Investors Deck February 2019 TASE: Cannassure Therapeutics Ltd

Size: px
Start display at page:

Download "Investors Deck February 2019 TASE: Cannassure Therapeutics Ltd"

Transcription

1 Investors Deck February 2019 TASE: Cannassure Therapeutics Ltd

2 2 Forward Looking Statements This presentation has been prepared by the Company and should not be considered as a recommendation or recommendation for the purchase or sale of securities and / or investment in Cannassure Therapeutics Ltd. This presentation is intended for the purpose of providing information only. The Company is not responsible and shall not be considered liable for any damage and / or loss that may be caused as a result of any information contained in this presentation and the use of this information. In addition, this presentation may include forward-looking information, as defined in the Israeli Securities Law, Such information includes, forecasts, estimates, estimates based on other information relating to future events and / or matters, the realization of which is uncertain and is not under the Company's control ("forwardlooking information."). Forward-looking information is not a proven fact and is based on subjective assumptions, estimates and forecasts made by the Company at that time only. The realization or non-realization of the forward- looking information may be affected from risk factors that characterize the company's operations, as well as from developments in the competitive and business environment and from external factors that influence the Company's operations, which cannot be foreseen and which are not controlled by the Company. Forward-looking information is not accurate, and the Company is unable to assess it in advance, as most of this information is not under its control. Therefore, this information, in whole or in part, may change substantially at any time as a result of the influence of various factors, including but not limited to changes in market conditions and / or competition in the market and / or in the business environment. The results and achievements of the Company in the future may be materially different than those presented in the presentation. In addition, forward-looking forecasts and evaluations are based to update evaluations so they would reflect events and/or circumstances that could appear after preparing this presentation.

3 3 Our Vision Cannassure's vision is to become a leading, world-class, trusted developer and provider of top-quality medical grade cannabis products as well as pharmaceutical cannabinoid medicines, addressing a broad range of unmet medical needs. Our Mission Cannassure will develop and commercialize a wide range of effective, high standard and affordable medical cannabis products as well as pharmaceutical cannabinoid medicines, to enhance treatment and improve people's quality of life worldwide. This will be accomplished by facilitating a holistic integrated production system including an advanced agritech breeding and cultivation indoor facility, a state-of-the-art extraction and processing facility, together with scientifically advanced R&D. Cannassure is committed to quality, excellence, innovation and integrity.

4 4 Our Company Cannassure (TASE symbol: CSURE) is launching a holistic and integrated medical cannabis value chain operation. Activity includes breeding, cultivation, extraction, R&D and distribution of medical cannabis products The company was founded by Solbar Food Technologies (~ 69.5%), a leading food manufacturer in Israel, with the intention of instilling its applied 60 years of industrial expertise and know-how Shareholder s equity includes ~ 51.2 Million outstanding shares and approx. 9.6 Million tradable stock options, divided into three series, with strike price of 2-3 ILS

5 5 Major Activities So Far In the process of extracting and processing, cannabis oil for the purpose of developing production procedures in the company's certified lab In the process of constructing an advanced, agritech indoor growing facility for cultivating uniform and consistent flowers, based on superior breeding strains In the process of constructing a cutting edge extraction and processing facility Signed distribution agreement with Hadassah Medical for marketing collaboration Established a highly experienced management team, skilled in international business, bio-tech and food manufacturing Initiated preliminary development plan for unique pharmaceutical cannabis products Granted financial support by the Israel Innovation Authority for the development of innovative cannabis extraction methods Received initial permits from the Israeli Medical Cannabis Authority (IMCA) for breeding, cultivating, processing, research and development (R&D) and storage of cannabis Signed binding MOU with Cannika Holdings, to establish an agritech incubator specializing in cannabis innovation, located within the company's campus

6 6 Solbar Food Technologies Group The group invested 17.5M ILS in Cannassure A 60-year-old leading company of high quality botanical extractions Customers over the years included global leading food and pharmaceutical companies, such as Unilever, Nestlé, Novartis, Janssen, Merck & GSK Cannassure is based on the know-how and experience of Solbar, including the extraction and processing of botanical extracts in a controlled environment and manufacturing in large industrial scale Annual income of 500M ILS Operates in accordance with quality standards Solbar provided Cannassure with labs and facilities spanning over 5,500 sqm

7 7 Executive Team Major General Ido Nehushtan Chairman of the Board Former commander of the Israel Air Force and Head of the IDF Planning Directorate, Mr. Nechushtan brings extensive managerial experience, including formulating strategy, creating work plans and leading processes. These he performed in the Air Force, the IDF and the private sector, in the fields of technology and cyber. He holds a B.Sc. cum laude in Mathematics and Computer Science from the Hebrew University of Jerusalem, an MBA from Northwestern University and Tel Aviv University, and an Advanced Management Program (AMP) from Harvard University. Nir Peles, CPA, MBA, MA(LAW) Founder, BOD Member & VP Business Development A seasoned entrepreneur with extensive knowledge in business development and company transformation. A former executive at Bluephoenix Solutions (NASDAQ: MDSY) and Alcobra Pharma (NASDAQ: ADHD), Mr. Peles holds a BA in Economics and Accountancy from the Hebrew University of Jerusalem and an MBA and MA (Law) degree from Tel Aviv and Bar Ilan Universities. Ran Amir CEO and BOD Member Having over 15 years of extensive international experience in operations management and management consulting, Mr. Amir has served 8 years in an executive position at The Bread Factory, a top of the range UK based food manufacturer, and 5 years as Solbar s CEO. Mr. Amir holds a B.Sc in Industrial Engineering and Management and M.Sc in International Business from Birkbeck, University of London. Dr. Hadile Ounallah-Saad VP R&D Bringing extensive experience in drug delivery systems and drug device combination; holding a Ph.D in Medical Science (neurobiology) from the Hadassah Medical School and a postdoctoral training in neurobiology from Haifa University, where she was appointed for a postdoctoral fellowship, Eshkol Laurate, on novel approaches for Alzheimer Disease therapy. Her field of expertise is neurodegenerative disorders.

8 8 Executive Team Steven Eitan VP Strategy Bringing 30 years of experience in leading and managing international biomed and hi-tech companies from start-up to market penetration and sales, including business and clinical strategy, raising finance, technological development, establishing marketing and sales systems. Over the years, Steven has managed publicly traded companies including Exalenz Bioscience (TASE: EXEN) and Micromedic Technologies (TASE: MCTC). Adi Neufeld CFO With 13 years of experience in various finance positions, Mr. Neufeld has served three years as the CFO of Solbar Food Technologies. Previously, Mr. Neufeld held positions at CHS Inc (NASDAQ: CHSCP). U.S. headquarters working for their Processing and Food Ingredients Division and at PWC Israel. Mr. Neufeld earned his Bachelor's Degree in Accounting and Economics from the Ben- Gurion University of the Negev. Dr. Hadar Less Agri-Consultant Dr. Less is a multi-disciplinary, R&D professional with unique expertise in Life Sciences, Genetics, and Bioinformatics. He has over a decade of experience leading R&D and operational business units for several international companies, including Syngenta (NASDAQ: SYENF) and Compugen (NASDAQ: CGEN). Dr. Less holds a Ph.D from the Weizmann Institute of Sciences, Department of Plant Science; an M.Sc in physiology and immunology from the Israel Institute of Technology s Faculty of Medicine; and a B.Sc in Animal Science from the Hebrew University of Jerusalem, Faculty of Agriculture. Dana Marom Chief Quality Manager With 15 years of extensive, international experience in Quality Management and R&D, Dana has previously served in senior management positions in companies such as GreenMarket, China and provided consulting services for the food manufacturing sector. Mrs. Marom holds a B.Sc in Biochemistry and Food Technology from the Hebrew University of Jerusalem and an EMBA from the College of Management Academic Studies.

9 9 Medical Cannabis- Opportunity and Global Market Trends Global cannabis market forecast growth Major trends in the medical cannabis global market: Widespread recognition of the virtues and effectiveness of medical cannabis products Significant increase in demand for medical cannabis treatments for dozens of medical indications Increased investments for research and development of medical cannabis products $28B by 2024 Increasing number of countries that authorized the use and trade of medical cannabis products Regulatory requirements reform for the use of medical cannabis products )MarketWatch, September 2018( Price reductions of raw cannabis yields, highlights the major business opportunity in the development and top-quality extraction of innovative medical cannabis products

10 10 Leading Cannabis Companies Company Symbol Trailing 12 months Revenues Market Cap Feb 1 st, 2019 Millions US dollars Billions US dollars Canopy Growth WEED.TO $73M $16.8B Tilray TLRY $33M $7.7B Aurora ACB.TO $60M $7.4B GW GWPH $13M $4.5B Cronos Inc CRON $9M $3.7B Aphria APHA $47M $2.4B

11 11 Cannassure is Establishing a Comprehensive Value Chain, Including All Stages of Medical Cannabis Production Breeding Cultivation Processing Development of unique cannabis strains Creating value for the medical cannabis and pharmaceutical industries, using advanced breeding technology Building an indoor growing facility Cultivation in a controlled environment, enabling quality consistent yields in accordance with (IMC - GAP) standards in 4000 sqm facility Extraction and processing of premium quality cannabis oil Large scale production of premium quailty cannabis oil, cannabinoid distillation and APIs, complying with Israeli Accreditation IMC - GMP, preparing for EU - GMP accreditation Distribution Distribution An agreement with Hadassah Medical for distribution to pharmaceutical companies, pharmacy outlets and licensed customers, in accordance with (IMC - GDP). Exploring additional opportunities with international affiliations R&D Development of unique medical products Patent protected, molecular based and cannabis specific for medical indications in large and growing global markets. Establishing a technological incubator for medical cannabis innovation, within the Cannassure campus, together with Cannika Holdings

12 12 Indoor Growing Facility Indoor cultivation enables quality and consistent products and has significant advantages including: Increase of annual growth cycles (approximately 6 cycles compared to 2-3 cycles in outdoor) Higher efficiency by savings in water and grow area ~ 20 tons potential annual capacity of cannabis flowers No exposure to weather conditions Cutlivation without herbicides and pesticides The facility is being built in an existing industrial building within the Solbar compound and will benefit from reduced-cost electricity, natural gas supply, reverse osmosis water supply and sewage treatment in accordance with environmental regulation The Cannassure Agronomy Team brings decades of experience of leading global agritech companies Cannassure is building its indoor growing facility in accordance with IMC - GAP agricultural standards

13 13 Medical Cannabis Extraction and Processing Cannassure is in advanced stages of building an IMC - GMP approved extraction facility for controlled production of high quality oils, cannabinoids and active pharmaceutical ingredients, aiming for EU - GMP The facility is being built using the accumulated expertise, know-how and experience of Solbar Group The construction of the facility is in accordance with the Ministry of Health's initial permit requirements Current extraction and processing activities in the company's lab: Developing and enhancing extraction techniques and stability testing in the company's lab, using state-ofthe-art equipment Developing analytical and bio-analytical techniques for the identification of single API's Product development is led by the company's scientific team, supported by a leading formulator and accompanied by leading regulatory advisors This activity has been acknowledged as innovative by the Israeli Innovation Authority and granted financial support

14 14 Hadassah Medical- A Strategic Partnership for Distribution in Israel and Commercial Activity Expansion in International Markets Cannassure has signed an agreement with Hadassah Medical for marketing and selling medical cannabis oil with the Hadassah Medical brand name in Israel and global markets Cannassure is planning to operate throughout Hadassah Medical's distribution channels, as well as exploring more collaborative mutual activity

15 15 Innovative Medical Cannabis Products Development Cannassure intends to develop and commercialize pharma-grade products, for life threatening diseases, in the field of oncological gynecology, using selected, active plant sourced cannabinoids The new product development is led by the company's scientific team, assisted by a senior formulator with regulatory guidance of several leading regulatory firms Cannassure is in the planning phase of developing a new product based on a combination of cannabinoid active ingredients together with an FDA approved gynecological medical device Cannassure is exploring options for leveraging the collaboration with Hadassah Hospital for the development of the product A proprietary patent application was filed by Cannassure's expert in pharmaceutical intellectual property, previously Intellectual Property Team Manager at Teva Pharmaceuticals

16 16 Medical Cannabis Innovative Center 1 Cannassure together with Cannika Holdings, a group of experienced scientific experts, are establishing an innovation center for early-stage medical cannabis unique innovative products 2 The center will operate in Cannassure's campus, utilizing state-of-the-art facilities, equipment, and technologies 3 Entrepreneurs joining the innovation center will benefit from a community of leading scientists, researchers and business professionals 4 The innovation center activity is financed by private investors

17 17 Next Steps, Key Milestones and onwards H2/2019 Extracting medical cannabis in the analytical laboratory Completion of extraction and processing facility, in accordance with IMC - GMP regulatory standards Completion of indoor grow facility for breeding new plant genetics and developing new strains, in accordance with IMC - GAP standards Ready for production and sale of IMC - GMP approved medical cannabis oil and cannabis API's

18 Cannassure's Competitive Advantages Summary 18 Founded on the know-how, experience and expertise of Solbar Group, a leader in the food and agriculture industry and benefits from its infrastructure and financial support Skilled highly experienced management team in international business, bio-tech, nutraceutical and food industries Rapidly establishing an indoor growing facility in a controlled environment, for premium quality and consistent cannabis flowers Equipped to meet and swiftly adjust to changing requirements, based on Solbar Group know-how and experience The global medical cannabis industry is undergoing rapid growth and development Rapidly establishing a highly professional complete value chain in the medical cannabis industry Infrastructure connected to reverse osmosis water supply, natural gas and cost-reduced electricity, allowing competitive, efficient and clean production environment Cannassure has clear competitive advantages to become a significant entity in the medical cannabis industry Strategic agreement with Hadassah Medical for collaboration and marketing of medical cannabis products worldwide Establishing a technological incubator for medical cannabis innovation within the company's campus

19 19 Thank You TASE: February 2019 Ran Amir

INVESTOR PRESENTATION!

INVESTOR PRESENTATION! INVESTOR PRESENTATION ENHANCING HEALTH THROUGH CANNABIS SCIENCE WWW.EMERALDHEALTH.CA TSX.V:EMH TSX.V:EMH Disclaimer THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING

More information

Cronos Capital

Cronos Capital Cronos Capital overview Overview Cronos Group, formerly known as PharmaCan Capital Corp., is a vertically integrated cannabis company with great geographical diversification as the foundation for growth

More information

Co C m o pa p n a y n Pr P o r f o il i e l Nove v mb m e b r r

Co C m o pa p n a y n Pr P o r f o il i e l Nove v mb m e b r r Company Profile November 2011 Migdal Underwriting & Business initiatives Ltd. Company Profile Migdal Underwriting & Business initiatives Ltd., is the investment banking arm of the Migdal Group, one of

More information

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within

More information

Established in 1934, Migdal is the leading insurance and finance group in Israel

Established in 1934, Migdal is the leading insurance and finance group in Israel Introduction The Migdal Group Overview Established in 1934, Migdal is the leading insurance and finance group in Israel Israel s largest insurance company Received Aaa perfect rating by Midrog (Moody s

More information

Leader in Pharmaceutical Films

Leader in Pharmaceutical Films TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation

More information

Creating a Social Investment Fund in Israel: Policy and Financial Considerations

Creating a Social Investment Fund in Israel: Policy and Financial Considerations February, 2014 No. 86 Creating a Social Investment Fund in Israel: Policy and Financial Considerations Daniela Kandel Milken Institute Fellow About the Milken Institute Fellows Program The Milken Institute

More information

Omeros Raises More Than $63 Million in Financing

Omeros Raises More Than $63 Million in Financing Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,

More information

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis

More information

TTC Introduction Meeting at: Carmiel, October 2014

TTC Introduction Meeting at: Carmiel, October 2014 TTC Introduction Meeting at: Carmiel, October 2014 IP Commercialization In recent years SNÈ / Rosetta managed to accomplish the following : +15 Million USD from IP Licensing +2 Million USD from Engineering

More information

Chairman of Trendlines Medical Singapore Todd Dollinger added, We are pleased to work

Chairman of Trendlines Medical Singapore Todd Dollinger added, We are pleased to work Singapore government investment arm of SPRING SEEDS Capital backs Trendlines Medical Singapore and Ozi Amanat s K2 Global to collaborate in its SGD100M investment allocation for tech start-ups Misgav,

More information

ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital

ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital August 14, 2017 ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital To Acquire One of Ten License Holders in New

More information

Global Alzheimer s Association Interactive Network. Imagine GAAIN

Global Alzheimer s Association Interactive Network. Imagine GAAIN Global Alzheimer s Association Interactive Network Imagine the possibilities if any scientist anywhere in the world could easily explore vast interlinked repositories of data on thousands of subjects with

More information

Mara H. Rogers, Partner Norton Rose Fulbright

Mara H. Rogers, Partner Norton Rose Fulbright Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers

More information

HOTELS, TOURISM & LEISURE. Hotels, Tourism & Leisure

HOTELS, TOURISM & LEISURE. Hotels, Tourism & Leisure HOTELS, TOURISM & LEISURE nem is one of Australasia s largest boutique business consultancy firms, which is able to draw on the significant skills and experience of over 50 partners across Australia and

More information

THE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES

THE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES THE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES Join us for a very special program co-hosted the HBS Alumni of Boston (HBSAB), The Harvard Stem Cell Institute (HSCI), and the Harvard NeuroDiscovery

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

Lehigh University Team biographies. October 30, 2017

Lehigh University Team biographies. October 30, 2017 Lehigh University Team biographies October 30, 2017 Core team members 2 Lane McBride Partner and Managing Director, Washington, DC Lane McBride is a Partner and Managing Director in the Washington, D.C.

More information

PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS

PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS PRESS RELEASE FOR IMMEDIATE RELEASE PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP Plasminogen BLA

More information

NIHR ROADSHOW FOR MEDTECH SMES

NIHR ROADSHOW FOR MEDTECH SMES MARTIN HUNT, DIRECTOR FOR INVENTION FOR INNOVATION (i4i) PROGRAMME, NATIONAL INSTITUTE FOR HEALTH RESEARCH Martin is Programme Director for i4i, a translational funding programme. i4i aims to support and

More information

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number

More information

Digital Health Startups A FirstWord ExpertViews Dossier Report

Digital Health Startups A FirstWord ExpertViews Dossier Report AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in

More information

PROGRAM ANNOUNCEMENT. New Jersey Institute of Technology. MSPhM Systems Engineering. Newark. Fall 2008

PROGRAM ANNOUNCEMENT. New Jersey Institute of Technology. MSPhM Systems Engineering. Newark. Fall 2008 PROGRAM ANNOUNCEMENT November 2007 Institution: New Program Title: Degree Designation: Degree Abbreviation: CIP Code and Nomenclature (if possible): Campus(es) where the program will be offered: Date when

More information

USP Research & Innovation Program

USP Research & Innovation Program USP Research & Innovation Program Ding Ming, Ph.D. Vice president, Research & Innovation United States Pharmacopeial Convention (USP) October 13, 2016 USP Programs and Products Impact Millions Worldwide

More information

Investor Presentation

Investor Presentation Investor Presentation January/February 2018 TSX-V: ABCN 1 Disclaimer Certain information included in this presentation, which was prepared on January 8, 2018 speaks only as of such date, including any

More information

ianthus Closes Acquisition of Citiva Medical and Citiva USA, Gaining Access to New York's Population of Approximately 20 Million People

ianthus Closes Acquisition of Citiva Medical and Citiva USA, Gaining Access to New York's Population of Approximately 20 Million People February 1, 2018 ianthus Closes Acquisition of Citiva Medical and Citiva USA, Gaining Access to New York's Population of Approximately 20 Million People Company to Host a Conference Call at 9:00am ET on

More information

Management to Host Conference Call at 8:30 a.m. ET today

Management to Host Conference Call at 8:30 a.m. ET today Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),

More information

NASDAQ: CASI Partnering Presentation

NASDAQ: CASI Partnering Presentation NASDAQ: CASI Partnering Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to

More information

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context

More information

The opportunity of the Israeli market

The opportunity of the Israeli market The opportunity of the Israeli market High Potential for a Bio-Pharma Industry in Israel Excellent Academic Infrastructure World Leadership in # of Granted Patents per Capita Rapid growth in Life sciences

More information

The Migdal Group Organizational Structure

The Migdal Group Organizational Structure Company Profile The Migdal Group Organizational Structure Public 69.15% 9.8% Migdal Insurance 21.05% 100% Migdal Capital Markets Alternative Investments Mutual Funds Underwriting and Business Initiatives

More information

First Southern Securities, LLC Credentials

First Southern Securities, LLC Credentials First Southern Securities, LLC Credentials Table of Contents SECTION A SECTION B SECTION C SECTION D Overview of First Southern Securities, LLC......3 Services Offered...6 Trading Volume by Credit 1. Municipal...11

More information

FINC915 Venture Lab Participating Firms: FALL 2010

FINC915 Venture Lab Participating Firms: FALL 2010 FINC915 Venture Lab Participating Firms: FALL 2010 Please Note: The listed firms will consider candidates. Not all firms will eventually offer a position to students. LOCAL FIRMS: I2A Fund Number of slots:

More information

Igor Fisch. New candidate, independent

Igor Fisch. New candidate, independent Igor Fisch New candidate, independent Igor Fisch is a co-founder of Selexis SA, a biotech company based in Switzerland. He grew the company from inception to profits in less than 5 years with up to > 5MCHF

More information

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd.

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd. IVC-MEITAR HIGH-TECH EXITS H1/ 215 REPORT IVC-Meitar 214 Exits Report Prepared by IVC Research Center Ltd. Israeli High-Tech Exit Highlights Exit proceeds in H1/215 reached ¾ of total exits for 214 Average

More information

An Experienced Approach to Private Equity

An Experienced Approach to Private Equity An Experienced Approach to Private Equity Monument MicroCap Partners, LLC (MMP) is an independent private investment firm comprised of highly experienced and accomplished private equity and operational

More information

BOND OVERSIGHT COMMITTEE 2017

BOND OVERSIGHT COMMITTEE 2017 BOND OVERSIGHT COMMITTEE 2017 The Coppell ISD seeks to involve our citizens in overseeing the 2016 Bond Program, including all projects approved by voters on May 7, 2016. INFORMATION UPDATED SEPTEMBER

More information

The MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009

The MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009 The MoneyTree Report Overview of Venture Capital Investments Third Quarter 2009 PricewaterhouseCoopers/National Venture Capital Association MoneyTree Report based on data from Thomson Reuters 1 Host of

More information

Investment Highlights. Investments

Investment Highlights. Investments Aphria overview Overview Aphria produces, supplies, and sells medical cannabis in Canada. The company sells its products through its online store or phones, as well as engages in the wholesale shipping

More information

Biotech Concerto #6 Investment Process December 2008

Biotech Concerto #6 Investment Process December 2008 Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision

More information

Beleave Signs Agreement to Acquire 250,000 Square Feet of Greenhouse Space and 85 Acres of Land to Expand its Production Capabilities

Beleave Signs Agreement to Acquire 250,000 Square Feet of Greenhouse Space and 85 Acres of Land to Expand its Production Capabilities Beleave Signs Agreement to Acquire 250,000 Square Feet of Greenhouse Space and 85 Acres of Land to Expand its Production Capabilities Toronto, ON September 6, 2018 Beleave Inc. (CSE: BE) (OTCQX: BLEVF)

More information

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your

More information

Joint Venture Announcement. 27 August 2018

Joint Venture Announcement. 27 August 2018 Joint Venture Announcement 27 August 2018 1 JV Stake - 51:49 51% 49% Combine Initial Total Investment of Rs. 60 Crores 2 Specialized Products to address High End Category Rough Terrain Crane Truck Cranes

More information

Commercialization Strategies that Work

Commercialization Strategies that Work Commercialization Strategies that Work Jenny C. Servo, Ph.D. DAWNBREAKER (585)594-0025 DAWNBREAKER Professional Services firm - Rochester, NY Worked with over 1200 SBIR/STTR firms - Department of Energy,

More information

JUST SCRATCHING THE SERVICE

JUST SCRATCHING THE SERVICE CONTRACT MANUFACTURING, PACKAGING & NEW EQUIPMENT TECHNOLOGY FOR THE BIOPHARM/PHARMACEUTICAL INDUSTRY OFFICIAL MEDIA SPONSOR OF W W W. P H A R M P R O. C O M V O L U M E 3 0, N U M B E R 4 M AY 2 0 1 5

More information

STEMEDICA EXPANDS GLOBALLY WITH INTERNATIONAL HEADQUARTERS IN SWITZERLAND

STEMEDICA EXPANDS GLOBALLY WITH INTERNATIONAL HEADQUARTERS IN SWITZERLAND STEMEDICA EXPANDS GLOBALLY WITH INTERNATIONAL HEADQUARTERS IN SWITZERLAND For Immediate Release SAN DIEGO, California (April 9, 2009) Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell

More information

Corporate Mind 2016 Corporate Responsibility Report

Corporate Mind 2016 Corporate Responsibility Report Corporate Mind 2016 Corporate Responsibility Report Promega uses an image of an animal cell to represent corporate organization because the cell represents non-hierarchical, interdependent structure. Corporate

More information

Purvi B. Maniar Member of the Firm

Purvi B. Maniar Member of the Firm Purvi B. Maniar Member of the Firm New York 250 Park Avenue New York, New York 10177 Tel: 212-351-3757 Fax: 212-878-8600 St. Louis Tel: 314-395-2775 pmaniar@ebglaw.com PURVI B. MANIAR is a Member of the

More information

Driving Israel s Economy and Helping People Worldwide

Driving Israel s Economy and Helping People Worldwide TECHNION IMPACT Driving Israel s Economy and Helping People Worldwide Founded in 1912, the Technion-Israel Institute of Technology is a world-leading science and technology university based in Haifa, Israel.

More information

Leadership Team. Mark van Berkel President and Chief Executive Officer

Leadership Team. Mark van Berkel President and Chief Executive Officer Mark van Berkel President and Chief Executive Officer Mark van Berkel is president and chief executive officer of TrueNorth Avionics, leading the company s strategy and overall direction. A cofounder of

More information

Local Production of Pharmaceuticals and Related Technology Transfer UNCTAD/CD-TFT 1. Background

Local Production of Pharmaceuticals and Related Technology Transfer UNCTAD/CD-TFT 1. Background Local Production of Pharmaceuticals and Related Technology Transfer Dr. Padmashree Gehl Sampath Division for Technology and Logistics UNCTAD UNCTAD/CD-TFT 1 1 Background Case studies part of the EU funded

More information

NEWS RELEASE. Life sciences companies tout their expertise in India

NEWS RELEASE. Life sciences companies tout their expertise in India For Immediate Release 2014MIT0016-000196 Feb. 19, 2014 NEWS RELEASE International Trade and Responsible for the Asia Pacific Strategy and Multiculturalism Life sciences companies tout their expertise in

More information

peace of mind For from development to commercial supply

peace of mind For from development to commercial supply For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number

More information

2. What is Text Mining? There is no single definition of text mining. In general, text mining is a subdomain of data mining that primarily deals with

2. What is Text Mining? There is no single definition of text mining. In general, text mining is a subdomain of data mining that primarily deals with 1. Title Slide 1 2. What is Text Mining? There is no single definition of text mining. In general, text mining is a subdomain of data mining that primarily deals with textual documents rather than discrete

More information

Other appointments: Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT.

Other appointments: Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT. Executive Committee Guido Oelkers Chief Executive Officer Born 1965. Employed since 2017. PhD in Strategic Management, University of South Australia, Master of Economics, South Bank University, London,

More information

FDA Centers of Excellence in Regulatory and Information Sciences

FDA Centers of Excellence in Regulatory and Information Sciences FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in

More information

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences

More information

For personal use only

For personal use only 2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor

More information

The Sherwin-Williams Company

The Sherwin-Williams Company The Sherwin-Williams Company "What is Worth Doing is Worth Doing Well." Founded in 1866 in Cleveland, Ohio #1 coatings company in the Americas #3 coatings company worldwide Over 40,000 employees worldwide

More information

UBS Global Healthcare Services Conference February 14, 2006

UBS Global Healthcare Services Conference February 14, 2006 UBS Global Healthcare Services Conference February 14, 2006 Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties including, but not

More information

Venture Capital Search Highlights

Venture Capital Search Highlights Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more

More information

Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization

Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization Accenture Life Sciences Rethink Reshape Restructure for better patient outcomes Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization Accenture Research Note: Key findings

More information

Overview of Venture Equity

Overview of Venture Equity Overview of Venture Equity SVB Analytics Report 2017 Written by SVB Analytics: Steve Liu Managing Director sliu@svb.com Sean Lawson Senior Manager slawson2@svb.com Steven Pipp Senior Associate spipp@svb.com

More information

Lupin Limited Annual Results FY12. Investor Presentation May being

Lupin Limited Annual Results FY12. Investor Presentation May being Lupin Limited Annual Results FY12 Investor Presentation May 2012 Vision: To be an innovation led transnational company Journey over the last decade 5th largest generics player in US Gross Revenues INR

More information

ALANCO TECHNOLOGIES INC

ALANCO TECHNOLOGIES INC SECURITIES & EXCHANGE COMMISSION EDGAR FILING ALANCO TECHNOLOGIES INC Form: 8-K Date Filed: 2016-10-04 Corporate Issuer CIK: 98618 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution

More information

Medicines Manufacturing in the UK 2017

Medicines Manufacturing in the UK 2017 Medicines Manufacturing in the UK 2017 Moderator: Magda Papadaki, PhD Head of Manufacturing Innovation The Association of the British Pharmaceutical Industry Medicines Manufacturing Industry Partnership

More information

Trends in Healthcare Investments and Exits 2018

Trends in Healthcare Investments and Exits 2018 Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview

More information

Offshore Renewable Energy Catapult

Offshore Renewable Energy Catapult Offshore Renewable Energy 7 s s: A long-term vision for innovation & growth The centres have been set up to make real changes to the way innovation happens in the UK to make things faster, less risky and

More information

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research Life Sciences Long Island 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research Suffolk County Stony Brook University serves as an integral part of the research corridor

More information

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Pharmaceutical Products and Services

Pharmaceutical Products and Services Pharmaceutical Products and Services Johnson Matthey (JM) combines specialist expertise and a 200-year heritage, to deliver a collaborative service offering focused on strengthening your products to ensure

More information

Life Sciences Outlook. Long Island 2016

Life Sciences Outlook. Long Island 2016 Life Sciences Outlook Long Island 2016 Long Island The Long Island life sciences landscape will continue to fuel the economy as firms emerge from Cold Spring Harbor Laboratory in Nassau County, as well

More information

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? M ost

More information

An Introduction to China s Science and Technology Policy

An Introduction to China s Science and Technology Policy An Introduction to China s Science and Technology Policy SHANG Yong, Ph.D. Vice Minister Ministry of Science and Technology, China and Senior Fellow Belfer Center for Science and International Affairs

More information

THE GOLDMAN SACHS GROUP, INC.

THE GOLDMAN SACHS GROUP, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

Israel Venture Capital Investments Report Q3 2017

Israel Venture Capital Investments Report Q3 2017 Israel Venture Capital Investments Report Q3 2017 NOVEMBER 2017 Summary of Israeli Venture Capital Raising Q3/2017 +14% from Q2/2017 Israeli high-tech capital raising summed up to $1.44B @ ALL RIGHTS RESERVED.

More information

The VIMS mission is to achieve and maintain a national and international position as a premier coastal marine science institute. This involves making

The VIMS mission is to achieve and maintain a national and international position as a premier coastal marine science institute. This involves making The VIMS Campus. The VIMS mission is to achieve and maintain a national and international position as a premier coastal marine science institute. This involves making seminal advances in knowledge and

More information

Generex Announces Appointment of Executive Management Team

Generex Announces Appointment of Executive Management Team Generex Announces Appointment of Executive Management Team Company Integrates Latest Acquisition and Builds Corporate Foundation for Growth MIRAMAR, FL, November 15, 2018 -- Generex Biotechnology Corporation

More information

Top 50 Emerging Technologies & Growth Opportunities

Top 50 Emerging Technologies & Growth Opportunities Top 50 Emerging Technologies & Growth Opportunities Multi-billion Dollar Technologies Ready to Energize Industries and Transform our World THE VALUE PROPOSITION TechVision s annual Top 50 Emerging Technologies

More information

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in Feature Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia Based on our long-term strategic vision toward 2020, our goal is to become #1 in Asia in terms of our

More information

Nasir, Dao PKM Abdul Partner PwC Legal (Vietnam) Co., Ltd

Nasir, Dao PKM Abdul Partner PwC Legal (Vietnam) Co., Ltd Nasir, Dao PKM Abdul Partner PwC Legal (Vietnam) Co., Ltd Get in touch Tel. (direct): +84 (8) 3824 0109 nasir.pkm@pwc.com Professional profile Nasir is a partner and the Legal Services Leader in Vietnam.

More information

THE GOLDMAN SACHS GROUP, INC.

THE GOLDMAN SACHS GROUP, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

Investor Presentation. May 2016

Investor Presentation. May 2016 Investor Presentation May 2016 Disclaimer This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward

More information

18 December University of Oxford Department of Materials Alfred Wong DPhil (Materials) 1993

18 December University of Oxford Department of Materials Alfred Wong DPhil (Materials) 1993 18 December 2008 University of Oxford Department of Materials Alfred Wong DPhil (Materials) 1993 My history with P&G Began DPhil in Biomaterials Group in September 1990. Attended P&G PhD Seminar in December

More information

Flexible Solutions for Business Owners

Flexible Solutions for Business Owners Flexible Solutions for Business Owners ERISBEG IS AN IRISH COMPANY THAT ACQUIRES AND FURTHER DEVELOPS ESTABLISHED BUSINESSES IN IRELAND AND INTERNATIONALLY Erisbeg is particularly focused on acquiring,

More information

Rick Legleiter Appointed Chief Executive Officer, Chairman Succession and Board Renewal Process

Rick Legleiter Appointed Chief Executive Officer, Chairman Succession and Board Renewal Process Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com

More information

MENTORS REGULATORY AFFAIRS. Christophe AMIEL Head of Medical Device & Digital, Voisin Consulting Life Sciences STRATEGY/BUSINESS

MENTORS REGULATORY AFFAIRS. Christophe AMIEL Head of Medical Device & Digital, Voisin Consulting Life Sciences STRATEGY/BUSINESS Hosted by : INNOLABS IDEAS CONTEST 21 st -22 nd June, Paris MENTORS REGULATORY AFFAIRS Christophe Amiel is heading the design and operational implementation of international regulatory strategies as Senior

More information

Technology Leadership Course Descriptions

Technology Leadership Course Descriptions ENG BE 700 A1 Advanced Biomedical Design and Development (two semesters, eight credits) Significant advances in medical technology require a profound understanding of clinical needs, the engineering skills

More information

Promoting Foreign Direct Investment in The United States. Christopher Clement International Investment Specialist Invest in America

Promoting Foreign Direct Investment in The United States. Christopher Clement International Investment Specialist Invest in America Promoting Foreign Direct Investment in The United States Christopher Clement International Investment Specialist Invest in America FDI in the U.S. Economy 5.2 million $40 billion $55 billion $190 billion

More information

Use of IP System for Research and Development Institutions and business Competitiveness. National Technology Business Centre

Use of IP System for Research and Development Institutions and business Competitiveness. National Technology Business Centre Use of IP System for Research and Development Institutions and business Competitiveness National Technology Business Centre MESVTEE INSTITUTIONS Ministry of Education, Science, Vocational Training and

More information

Life Sciences Outlook. New York City 2016

Life Sciences Outlook. New York City 2016 Life Sciences Outlook City 2016 City is emerging as a leading destination for biotech startups and the larger life sciences industry. Investors have committed millions of dollars throughout the city and

More information

INVESTOR BRIEFING NOTE NOVEMBER 2017

INVESTOR BRIEFING NOTE NOVEMBER 2017 INVESTOR BRIEFING NOTE NOVEMBER 2017 RavenQuest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized

More information

MITHRA PHARMACEUTICALS ANNOUNCES ITS FIRST HALF 2016 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

MITHRA PHARMACEUTICALS ANNOUNCES ITS FIRST HALF 2016 FINANCIAL RESULTS AND OPERATIONAL PROGRESS REGULATED INFORMATION MITHRA PHARMACEUTICALS ANNOUNCES ITS FIRST HALF 2016 FINANCIAL RESULTS AND OPERATIONAL PROGRESS Liège, Belgium 1 September 2016, 07h30 Mithra Pharmaceuticals, a leader in Women s

More information

Cross-Border R&D in China Understanding the Regulatory Challenges

Cross-Border R&D in China Understanding the Regulatory Challenges 1 2 Cross-Border R&D in China Understanding the Regulatory Challenges 1 Panelists Moderator: Paul A. Stewart, Silicon Valley Office Managing Partner, Foley & Lardner LLP Speakers: David Rosen, Partner,

More information

PRESS RELEASE FOR IMMEDIATE RELEASE NEX SYMBOL: AXQ JULY 25, 2018

PRESS RELEASE FOR IMMEDIATE RELEASE NEX SYMBOL: AXQ JULY 25, 2018 PRESS RELEASE FOR IMMEDIATE RELEASE NEX SYMBOL: AXQ JULY 25, 2018 RE: ACQUISITION OF TERRANUEVA PHARMA CORPORATION FOR $10,930,000 - CHANGE OF NAME - CONSOLIDATION - ANNOUNCEMENT OF A CONCURRENT PRIVATE

More information

KANSAS BIOSCIENCE INDEX 2008

KANSAS BIOSCIENCE INDEX 2008 Innovation Capacity Education Capacity Workforce Capacity KANSAS BIOSCIENCE INDEX 2008 Industrial Output Prepared by: Research & Development Capacity ACKNOWLEDGEMENTS The Bioscience Authority contracted

More information

EXECUTIVE SUMMARY. Investment Opportunity. Paradox Financial Solutions Inc.

EXECUTIVE SUMMARY. Investment Opportunity. Paradox Financial Solutions Inc. An innovative new system for Supply Chain Financing that is so disruptive that it will revolutionize the way in which practices in B2B trading relationships occur. has invented a system that revolutionizes

More information

gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) Web gellerbp.

gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) Web gellerbp. gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) 315-0600 Web gellerbp.com Summary Personal Diverse, world-class team of top biotech bankers,

More information

9 Vaccine SMEs' Needs

9 Vaccine SMEs' Needs 9 Vaccine SMEs' Needs As in most innovative sectors, SMEs play a critical role in bridging basic discoveries from academic research to clinical development 36. This could be seen over the last decade with

More information

National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs

National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs Jeff Shuren Director, CDRH Food and Drug Administration Center for Devices and Radiological Health 1 We face a critical public

More information